Federated Hermes Inc. Has $1.13 Million Holdings in Organon & Co. (NYSE:OGN)

Federated Hermes Inc. increased its position in Organon & Co. (NYSE:OGN) by 4.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 75,677 shares of the company’s stock after purchasing an additional 3,169 shares during the period. Federated Hermes Inc.’s holdings in Organon & Co. were worth $1,129,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Horizon Bancorp Inc. IN lifted its holdings in shares of Organon & Co. by 2,401.5% in the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock valued at $25,000 after purchasing an additional 1,585 shares in the last quarter. Millstone Evans Group LLC purchased a new stake in Organon & Co. in the 4th quarter worth about $29,000. Larson Financial Group LLC boosted its position in Organon & Co. by 345.4% during the 4th quarter. Larson Financial Group LLC now owns 2,236 shares of the company’s stock worth $33,000 after acquiring an additional 1,734 shares during the period. Riverview Trust Co grew its stake in Organon & Co. by 117.7% during the 4th quarter. Riverview Trust Co now owns 2,390 shares of the company’s stock valued at $36,000 after acquiring an additional 1,292 shares in the last quarter. Finally, Versant Capital Management Inc grew its stake in Organon & Co. by 92.2% during the 4th quarter. Versant Capital Management Inc now owns 2,760 shares of the company’s stock valued at $41,000 after acquiring an additional 1,324 shares in the last quarter. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Organon & Co. Stock Performance

OGN stock opened at $11.29 on Tuesday. The firm has a 50 day moving average of $14.56 and a two-hundred day moving average of $15.59. Organon & Co. has a 12 month low of $10.94 and a 12 month high of $23.10. The company has a market capitalization of $2.91 billion, a price-to-earnings ratio of 3.39, a P/E/G ratio of 0.90 and a beta of 0.73. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). The business had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. As a group, equities analysts anticipate that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were paid a dividend of $0.28 per share. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 annualized dividend and a dividend yield of 9.92%. Organon & Co.’s dividend payout ratio (DPR) is presently 33.63%.

Analyst Ratings Changes

Several analysts recently commented on OGN shares. Morgan Stanley decreased their price target on shares of Organon & Co. from $16.00 to $15.00 and set an “equal weight” rating for the company in a report on Wednesday, April 9th. TD Cowen raised shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. Finally, Barclays dropped their price target on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. One research analyst has rated the stock with a sell rating, three have given a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $20.60.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.